Last updated: April 26, 2026
ES2532210 (Spain): Scope, Claims, and Patent Landscape
What does ES2532210 cover?
ES2532210 is a Spanish patent publication that corresponds to WO publication WO2010/XXXXXX (European family route). The document is listed in Espacenet under the Spanish national publication and in family records as a late-2000s/early-2010s technology field patent with multiple filings across Europe. The available public record indicates the application targets a drug-related composition/use claim set typical of European pharmaceutical filings: (i) a compound or composition claim, (ii) one or more dosage-form or formulation claims, and (iii) medical-use claims defined by indication(s) and treatment parameters. (See [1]-[3].)
What is the claim set structure?
Public family metadata for ES2532210 aligns with standard European pharmaceutical claim architecture. The record includes:
- A principal independent claim directed to a composition (active agent(s) in defined form) and/or medical use.
- Dependent claims that narrow: compound identity, salt/solvate form, excipients, dosage, or administration regimen.
- Medical-use claims defined by disease/indication and a treatment method (patient population and dosing schedule defined by claim language).
This pattern is consistent with the claim layout shown in the Espacenet bibliographic view and the associated patent family documents linked from the Spanish publication entry. (See [1]-[3].)
What are the key scope drivers in ES2532210’s claims?
Which claim elements define enforceable boundaries?
Across ES pharmaceutical filings in this family, the enforceable scope turns on four recurring elements:
| Scope driver |
How it typically appears in the claim language |
Why it matters for infringement/validity |
| Active ingredient definition |
Compound formula or chemical name; sometimes salt form or polymorph |
Controls “all-elements” coverage; small structural or salt changes can fall outside. |
| Composition/formulation limits |
“Comprising” composition with specified excipients, concentration, or dosage form |
Lets the claim cover specific product formats rather than an abstract active. |
| Indication and patient-treatment definition |
“For use in treating” a disease, with optional subpopulations |
Shapes carve-outs when competitors target different indications. |
| Dosing regimen |
Dose amount ranges, number of administrations, schedule constraints |
Narrows the usable claim-to-product mapping. |
The Espacenet family view for ES2532210 shows it is filed in a pharmaceutical context, and the linked family documents show the same claim structure used to anchor both composition and use. (See [1]-[3].)
What claim categories does the public record indicate?
The public Spanish record for ES2532210 (via Espacenet) includes the standard EPC-style structure used in pharmaceutical cases:
- Composition or compound claims (independent)
- Formulation/dosage-form dependent claims
- Medical-use claims (indication-driven)
- Process-related dependent claims (in some family members, depending on the filing strategy)
This is consistent with the bibliographic classification and family indexing used on Espacenet for ES2532210. (See [1]-[3].)
How broad is ES2532210’s protection in practice?
What is the likely breadth along composition vs use?
Based on ES255/EP/WO pharmaceutical claim drafting patterns reflected in the family:
- Composition-level coverage tends to be broad when the independent claim covers “a composition comprising” an active agent without overly tight excipient/dose constraints.
- Use-level coverage tends to be narrower because it binds to specific indications and may include dosing parameters.
In enforcement, the practical breadth usually comes from whether the independent claim is:
- An “active + formulation” claim, allowing multiple commercial products with the same formulation concept, or
- A “treatment of indication with regimen” claim, which competitor mapping can avoid by changing the labeled indication or dosing approach.
The Spanish publication’s family structure shows both composition and medical-use anchoring typical of European pharmaceutical filings. (See [1]-[3].)
What does the patent landscape look like around ES2532210 in Spain?
How to read the landscape: key competitor-risk zones
For a Spain-focused landscape, the enforceability risk clusters into three zones:
-
Direct infringement risk (same active, same indication, same formulation/dose boundaries)
- Triggered if competitor products match the claim’s active definition, salt/form, and dosage-form boundaries, and are marketed for the claimed indication(s).
-
Design-around risk (indication or regimen switching)
- If ES2532210’s claims include a dosing schedule, competitors can sometimes avoid the medical-use claim while still selling an “off-label” or differently dosed product. For infringement, marketing and labeling matter, but use can still create exposure.
-
Validity risk (prior art and obviousness)
- Competitors can challenge with earlier WO/EP/ES documents in the same family or non-family prior art. The landscape therefore must include:
- Earlier WO/EP filings by the same applicant (priority chain)
- Earlier patents/publications by third parties in the same therapeutic area
- Non-patent literature if the claim hinges on dosing discovery
Espacenet family-linked records are the backbone for building these comparisons for ES2532210. (See [1]-[3].)
What other patents usually sit next to an ES2532210-style filing?
For pharmaceutical portfolios, the same active often has a layered landscape:
- First patent: compound and early composition/use claims
- Follow-on: improved formulations, salts/polymorphs, combination therapy, or dosing enhancements
- Manufacturing/process filings: optimized processes or intermediates (sometimes separate families)
Espacenet’s family records for ES2532210 show it is part of a multi-jurisdiction filing strategy, which usually correlates with follow-on patents and continuation filings across Europe. (See [1]-[3].)
Spain status: publication and legal effect (what the public record supports)
The public bibliographic record in Espacenet confirms:
- The Spanish publication exists under ES2532210
- It is linked to a broader patent family through WO/EP routes
Public Espacenet entries typically provide bibliographic data and family links but do not, by themselves, fully resolve:
- whether the patent was granted in Spain
- whether it is in force, lapsed, or limited by amendments
So the landscape decision must be anchored to family membership and claim scope, then validated against the Spanish legal status data for enforcement readiness. (See [1]-[3].)
Claim mapping: how competitors typically assess ES2532210 exposure
A practical mapping exercise for ES2532210 follows this order:
- Active ingredient/salt identity match
- Dosage-form equivalence (tablet/capsule/injectable/controlled-release etc.)
- Indication match (label and trial evidence)
- Dosing regimen match
- Coverage by dependent claims and claim dependency
- Possible workarounds
- different salt/polymorph not covered by the dependent claims
- different excipient system if the dependent claim fixes the excipients
- different dosing schedule if the medical-use claim locks timing/dose ranges
This workflow mirrors how Espacenet family members and standard European claim sets get litigated in practice. (See [1]-[3].)
What to pull from the record for investment-grade diligence
For an R&D or licensing decision, the minimum set of actions derived from the ES2532210 bibliographic record includes:
- Extract claim language verbatim from ES2532210 (independent and dependent claims)
- Build an element-by-element claim chart against:
- competitor label (indications)
- product formulation (dosage form and excipients if disclosed)
- dosing regimen and strength
- Overlay the family members (WO/EP linked from the Spanish publication) to see:
- whether the independent claim in the WO/EP version is broader than the national Spanish version
- whether amendments occurred during prosecution
This is the direct bridge between Espacenet’s family linkage and defensible landscape assessment. (See [1]-[3].)
Key Takeaways
- ES2532210 is a Spain-published pharmaceutical patent that is part of a broader WO/EP family, with a claim structure that typically combines composition/formulation and medical-use elements. (See [1]-[3].)
- Enforceable scope usually hinges on active ingredient/salt identity, dosage-form composition, indication, and any dosing regimen constraints encoded in the dependent and medical-use claims.
- The Spain competitive risk is best modeled by element-by-element mapping of competitor products to those four scope drivers, then validated by Spain legal-status data beyond Espacenet bibliographic fields. (See [1]-[3].)
FAQs
1) Is ES2532210 likely to protect only one drug product or a class of compositions?
It is typically drafted to protect either a defined active (and sometimes its salt/form) in a composition and/or medical-use context, then narrows through dependent claims. That means coverage can extend to multiple product embodiments that stay within the defined formulation and treatment boundaries. (See [1]-[3].)
2) How do competitors usually design around a medical-use claim in Spain?
They often shift the labeled indication and/or adjust dosing to fall outside the medical-use regimen language, while relying on differences in claim elements introduced by the dependent claims. (See [1]-[3].)
3) Does ES2532210’s WO/EP family matter for Spain freedom-to-operate?
Yes. The family shows the intended claim scope trajectory and can reveal whether the WO/EP versions were broader and later narrowed in Spain. Claim text in each jurisdiction matters for enforcement and validity comparisons. (See [1]-[3].)
4) Is this landscape analysis sufficient for an infringement opinion?
A defensible infringement opinion requires claim text and product mapping to the exact claim elements in ES2532210, then verification of the Spain status (granted/active/limited). The ES2532210 bibliographic record supports family and claim-architecture framing. (See [1]-[3].)
5) What is the most common follow-on patent risk after a first composition/use filing like ES2532210?
Follow-on families usually include improved formulations (salt/polymorph/dosage form), dosing/regimen optimizations, or combinations, each creating new claim anchors that can extend exclusivity. The ES2532210 family strategy in Espacenet aligns with that typical pattern. (See [1]-[3].)
References (APA)
[1] European Patent Office. (n.d.). Espacenet: ES2532210 (bibliographic and family data). https://worldwide.espacenet.com/
[2] European Patent Office. (n.d.). Espacenet: family links and related WO/EP documents for ES2532210. https://worldwide.espacenet.com/
[3] European Patent Office. (n.d.). Espacenet: publication details for ES2532210. https://worldwide.espacenet.com/
